Biocon Ltd. has launched its drug-device combination for diabetes and obesity, Diavorin and Vobexoryn respectively, in the Netherlands via Pharmamedic BV.

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Some patients dropped out of the trial early because they had lost so much weight.

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to ...

Get the latest stock market and healthcare sector updates, top gainers and losers, and key regulatory news impacting investments.

If you have ever wondered whether Regeneron Pharmaceuticals is a smart buy at around $718 a share, you are not alone; investors are trying to figure out if the current price really reflects its long ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...